Cross-border biotech deals between China and the United States are becoming more complex due to increased US investment and technology controls. Despite these challenges, Western pharmaceutical companies are expected to continue and even accelerate deal-making with Chinese counterparts. Analysts predict that the value of out-licensing agreements between Chinese biotech firms and Western drug makers will significantly increase, with only the largest pharmaceutical companies possessing the resources to navigate the evolving political landscape. AI
IMPACT Increased complexity in cross-border biotech deals may impact the pace of AI-driven drug discovery and development.
RANK_REASON Policy changes impacting cross-border investment in a significant industry. [lever_c_demoted from significant: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
